The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Shi, Jing ^a   van Steenbergen, Hanna W ^a   van Nies, Jessica A B ^a   Levarht, E W Nivine ^a   Huizinga, Tom W J ^a   van der Helm van Mil, Annette H M ^a   Toes, René E M ^a   Trouw, Leendert A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ACPA; Anti CarP antibodies; Rheumatoid arthritis

Indexed keywords

CARBAMYLATED PROTEIN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; CYANIDE; PROTEIN;

ANTIBODY DETECTION; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; AREA UNDER THE CURVE; BLOOD; IMMUNOLOGY; METABOLISM; PROTEIN PROCESSING; RECEIVER OPERATING CHARACTERISTIC;

AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BIOMARKERS; CYANIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84947927020     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0860-6     Document Type: Article

References (18)

1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-8.
2. Chatfield SM, Wicks IP, Sturgess AD, Roberts LJ. Anti-citrullinated peptide antibody: death of the rheumatoid factor? Med J Aust. 2009;190:693-5.
3. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 2011;108:17372-7.
4. Jiang X, Trouw LA, van Wesemael TJ, Shi J, Bengtsson C, Källberg H, et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis. 2014;73:1761-8.
5. Humphreys JH, Verheul MK, Barton A, MacGregor AJ, Lunt M, Toes RE, et al. Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2015-207326.
6. Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev. 2014;13:225-30.
7. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13:1176-4.
8. Nzeusseu Toukap A, Delporte C, Noyon C, Franck T, Rousseau A, Serteyn D, et al. Myeloperoxidase and its products in synovial fluid of patients with treated or untreated rheumatoid arthritis. Free Radic Res. 2014;48:461-5.
9. Yee A, Webb T, Seaman A, Infantino M, Meacci F, Manfredi M, et al. Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol Res. 2015;61:24-30.
10. Brink M, Verheul MK, Rönnelid J, Berglin E, Holmdahl R, Toes REM, et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther. 2015;17:25.
11. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Toes RE, Trouw LA, et al. Anti-carbamylated protein antibodies (anti-CarP) are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 2013;65:911-5.
12. Gan RW, Trouw LA, Shi J, Toes RE, Huizinga TW, Demoruelle MK, et al. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J Rheumatol. 2015;42:572-9.
13. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73:780-3.
14. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011;50:93-100.
15. Martin L, Steber WA, Lupton TL, Mahler M, Fitch CM, McMillan JD, et al. Clinical and serological analysis of patients with positive anticyclic citrullinated peptide antibodies referred through a rheumatology central triage system. J Rheumatol. 2015;42:771-7.
16. Payet J, Goulvestre C, Biale L, Avouac J, Wipff J, Job-Deslandre C, et al. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients. J Rheumatol. 2014;41:2395-402.
17. Van der Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De RL, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis. 2005;64:1145-9.
18. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094-108.